Cannabis Science Signs A New Non-Exclusive Commercial License Agreement with Rockbrook To Continue Its Strategic Partnersh

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science Inc. (NASD OTCBB: CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to update its shareholders that over the last month, Cannabis Science, Rockbrook and Mr. Adam Pasquale, its principal, have now signed a new non-exclusive commercial licensing agreement (“CLA”) and agreed to map out a plan to continue a mutually beneficial strategic partnership within the State of Colorado. Under the new agreement, Rockbrook will develop and distribute Cannabis Science’s proprietary medical cannabis delivery methods and formulations in the State of Colorado on a case by case basis.

The new agreement with Rockbrook will permit Cannabis Science to move forward expanding its licensing and product delivery capacity inside and outside of Colorado through new partnerships and license agreements to maximize market potential for the Company and shareholders.

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, “The new commercial license agreement with Rockbrook will continue to benefit both parties and we will continue to delivery our proprietary medical cannabis products and delivery methods through Rockbrook on a case by case basis. Rockbrook will also continue to share critical patient data with Cannabis Science to further our studies and product development.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.



CONTACT:

Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
[email protected]
or
Mark J. Friedman, Investor Relations
1-877-431-CBIS (2247)
[email protected]
www.cannabisscience.com

KEYWORDS:   United States  North America  California  Colorado

INDUSTRY KEYWORDS:   Health  Alternative Medicine  Public Policy/Government  Healthcare Reform  Pharmaceutical

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.